For the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder.
Methotrimeprazine's antipsychotic effect is largely due to its antagonism of dopamine receptors in the brain. In addition, its binding to 5HT2 receptors may also play a role.
Symptoms of overdose include convulsions, spastic movements, and coma.
Methotrimeprazine has an incomplete oral bioavailability, because it undergoes considerable first-pass-metabolism in the liver. Oral bioavailability is approximately 50 to 60%.
Approximately 20 hours.